(Q37855900)

24 August 2017

1 reference

title

HIV microbicides: state-of-the-art and new perspectives on the development of entry inhibitors (English)

1 reference

24 August 2017

3

1 reference

24 August 2017

4

1 reference

24 August 2017

Anna Bernardi

2

0 references

author name string

Jose J Reina

series ordinal

1

1 reference

24 August 2017

publication date

1 July 2010

1 reference

Future Medicinal Chemistry

24 August 2017

published in

1 reference

24 August 2017

volume

2

1 reference

24 August 2017

issue

7

1 reference

24 August 2017

page(s)

1141-1159

1 reference

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Microbicide drug candidates to prevent HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Vaginal microbicides and the prevention of HIV transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Whither or wither microbicides?

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Development of topical microbicides to prevent the sexual transmission of HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Which topical microbicides for blocking HIV-1 transmission will work in the real world?

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Vaginal microbicides: moving ahead after an unexpected setback

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Microbicides for HIV prevention: reality or hope?

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

C-type lectins on dendritic cells: key modulators for the induction of immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Innate signaling by the C-type lectin DC-SIGN dictates immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Pathogen recognition by DC-SIGN shapes adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Carbohydrate-specific signaling through the DC-SIGN signalosome tailors immunity to Mycobacterium tuberculosis, HIV-1 and Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Dusting the sugar fingerprint: C-type lectin signaling in adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

HIV-1 attachment: another look.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Evaluation of current approaches to inhibit HIV entry.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Blocking the docking of HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

21 January 2018

HIV entry inhibitors.

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

HIV entry inhibitors and their potential in HIV therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

HIV-1 entry inhibitors: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

CD4-anchoring HIV-1 fusion inhibitor with enhanced potency and in vivo stability.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Antiviral drug discovery: ten more compounds, and ten more stories (part B).

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Binding optimization through coordination chemistry: CXCR4 chemokine receptor antagonists from ultrarigid metal complexes.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Amine substituted N-(1H-benzimidazol-2ylmethyl)-5,6,7,8-tetrahydro-8-quinolinamines as CXCR4 antagonists with potent activity against HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

HIV co-receptor CCR5: structure and interactions with inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

CCR5 blockade modulates inflammation and alloimmunity in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Maraviroc: a new CCR5 antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-oxide (Sch-350634), an orally bioavailabl

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

1-Amido-1-phenyl-3-piperidinylbutanes - CCR5 antagonists for the treatment of HIV. Part 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

1-Amido-1-phenyl-3-piperidinylbutanes--CCR5 antagonists for the treatment of HIV: part 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

The design and discovery of novel amide CCR5 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

[2-(4-Phenyl-4-piperidinyl)ethyl]amine based CCR5 antagonists: derivatizations at the N-terminal of the piperidine ring

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

4,4-Disubstituted cyclohexylamine based CCR5 chemokine receptor antagonists as anti-HIV-1 agents

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Spiropiperidine CCR5 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Evaluation of secondary amide replacements in a series of CCR5 antagonists as a means to increase intrinsic membrane permeability. Part 1: Optimization of gem-disubstituted azacycles

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Structural and molecular interactions of CCR5 inhibitors with CCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

CCR5 small-molecule antagonists and monoclonal antibodies exert potent synergistic antiviral effects by cobinding to the receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR. Subunit organization and binding to multivalent ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

DC-SIGN: escape mechanism for pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

1,2-Mannobioside mimic: synthesis, DC-SIGN interaction by NMR and docking, and antiviral activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Non-carbohydrate inhibitors of the lectin DC-SIGN.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Synthesis of novel DC-SIGN ligands with an alpha-fucosylamide anchor.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

From carbohydrate leads to glycomimetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Distinct roles for DC-SIGN+-dendritic cells and Langerhans cells in HIV-1 transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Infection of dendritic cells (DCs), not DC-SIGN-mediated internalization of human immunodeficiency virus, is required for long-term transfer of virus to T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Dendritic cell-mediated trans-enhancement of human immunodeficiency virus type 1 infectivity is independent of DC-SIGN

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Glycodendritic structures: promising new antiviral drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Mannosyl glycodendritic structure inhibits DC-SIGN-mediated Ebola virus infection in cis and in trans

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Inhibition of DC-SIGN-mediated HIV infection by a linear trimannoside mimic in a tetravalent presentation.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I study.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Candidate polyanion microbicides inhibit HIV-1 infection and dissemination pathways in human cervical explants.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Enhancement of human immunodeficiency virus type 1 replication is not intrinsic to all polyanion-based microbicides.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

A synthetic CD4-heparan sulfate glycoconjugate inhibits CCR5 and CXCR4 HIV-1 attachment and entry.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

GP120: target for neutralizing HIV-1 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

HIV-1 and influenza antibodies: seeing antigens in new ways

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Inhibition of HIV entry by carbohydrate-binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Multivalent benzoboroxole functionalized polymers as gp120 glycan targeted microbicide entry inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Pradimicin S, a highly soluble nonpeptidic small-size carbohydrate-binding antibiotic, is an anti-HIV drug lead for both microbicidal and systemic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Discovery of 4-benzoyl-1-[(4-methoxy-1H- pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a d

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

The entry of entry inhibitors: a fusion of science and medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Potent D-peptide inhibitors of HIV-1 entry

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Anti-AIDS agents. 78. Design, synthesis, metabolic stability assessment, and antiviral evaluation of novel betulinic acid derivatives as potent anti-human immunodeficiency virus (HIV) agents

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Structure-based design, synthesis and biological evaluation of new N-carboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

In vitro synergistic activity against CCR5-tropic HIV-1 with combinations of potential candidate microbicide molecules HHA, KRV2110 and enfuvirtide (T20).

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Capture and transmission of HIV-1 by the C-type lectin L-SIGN (DC-SIGNR) is inhibited by carbohydrate-binding agents and polyanions

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Synergistic inhibition of HIV-1 infection by combinations of soluble polyanions with other potential microbicides

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Gold manno-glyconanoparticles: multivalent systems to block HIV-1 gp120 binding to the lectin DC-SIGN.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Safety concerns for the potential use of cyanovirin-N as a microbicidal anti-HIV agent

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

DC-SIGN promotes exogenous MHC-I-restricted HIV-1 antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Dendritic cells and HIV-specific CD4+ T cells: HIV antigen presentation, T-cell activation, and viral transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Activation of the lectin DC-SIGN induces an immature dendritic cell phenotype triggering Rho-GTPase activity required for HIV-1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

Mannose hyperbranched dendritic polymers interact with clustered organization of DC-SIGN and inhibit gp120 binding

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.10.203

21 January 2018

Identifiers

DOI

10.4155/FMC.10.203

1 reference

24 August 2017

1 reference